August 20, 2018
Source: CareFirst BlueCross BlueShield Press Release
CareFirst BlueCross BlueShield (CareFirst) and Exagen Diagnostics, Inc. (Exagen) today announced an agreement to collaborate to study the impact of Exagen’s proprietary AVISE Lupus test. As part of the agreement, select CareFirst members will have access to the AVISE Lupus test to aid in the differential diagnosis of systemic lupus erythematosus (SLE)…Currently, there is no single test to diagnose SLE. AVISE Lupus and its proprietary algorithm has been prospectively validated in clinical trials with over 1,200 patients demonstrating improved diagnostic accuracy compared to traditional biomarkers alone.
